Nevertheless, ex vivo immunohistochemistry revealed significant anti-angiogenic effects of bevacizumab in the investigated MDA-MB-231 human breast cancer model in mice, as indicated by the suppression of endothelial marker CD31 and αvß3-integrin expression under therapy. This evidence concerns the gene PECAM1 and breast cancer.